Medical Condition News

RSS

Osteoporosis drug reduces bone loss in oral cancer

A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.

14 Dec 2010

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

UCSF physicians are combating a devastating side effect of chemotherapy with an innovative new program -- "Hair to Stay" -- to evaluate devices that could reduce scalp hair loss in breast cancer patients.

14 Dec 2010

Drug to reverse immunological decline in aging

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.

14 Dec 2010

Novel labeling technique helps researchers to explore DNA chemical modification

Researchers at Emory University School of Medicine and the University of Chicago have developed a method for labeling and mapping a "sixth nucleotide," whose biological role scientists are only beginning to explore.

14 Dec 2010

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

Capstone Therapeutics announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid scarring and seven-month interim results of its ongoing AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.

14 Dec 2010

BUSM professor wins 2010 Van Slyke Award for seminal contributions to laboratory medicine

Michael F. Holick, PhD, MD, a professor at Boston University School of Medicine (BUSM), is the recipient of the 2010 Van Slyke Award from the American Academy for Clinical Chemistry New York Metro Section.

14 Dec 2010

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

14 Dec 2010

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

13 Dec 2010

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

Research: Kidney disease caused by autoimmune disease lupus may be twice as lethal in children

Kidney disease caused by the autoimmune disease lupus may be twice as lethal in children as kidney disease caused by other disorders, according to research led by Johns Hopkins Children's Center investigators.

13 Dec 2010

Alzheimer’s research update

Alzheimer’s disease researchers have been working for a while with a small, sticky protein fragment, beta amyloid, that clumps into balls in the brains of patients with this degenerative neurological disease. It is a normal protein that is present in every normal brain but in Alzheimer’s it starts to accumulate into these balls or plaques. On buildup of amyloid symptoms of the disease appear.

13 Dec 2010

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell AG announced today preliminary clinical results on its investigational Travelers' Diarrhea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India.

13 Dec 2010

Enrollment commences in multi-center clinical trial of CorMatrix ECM for Pericardial Closure

CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that Franciscan Alliance/St. Francis Heart Center in Indianapolis, Indiana is the first site to enroll a patient in the multi-center clinical trial of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation.

13 Dec 2010

$Indian study confirms vitamin D deficiency as risk factor for hip fracture$

Indian study confirms vitamin D deficiency as risk factor for hip fracture

A study from New Delhi India has revealed high rates of vitamin D deficiency among hip fracture patients, confirming the conclusions of similar international studies which point to vitamin D deficiency as a risk factor for hip fracture.

13 Dec 2010

Elsevier announces special Issue on Fetal Alcohol Spectrum Disorders

Elsevier Inc., the world's leading publisher of scientific, technical and medical information, announced today that Alcohol has published a special year-end double issue on Fetal Alcohol Spectrum Disorders (FASD). It fills an urgent need to bring the widest possible readership current perspectives on using new research methods to improve identification and diagnosis of offspring at risk for FASD and its associated brain damage and behavioral dysfunction.

13 Dec 2010

iTech Medical receives Health Canada approval for Muscle Pattern Recognition System

iTech Medical, Inc., a medical information technology company, announced today that it has received Health Canada approval for the Company's Muscle Pattern Recognition (MPR) System, a non-invasive clinical assessment tool being developed to assist in the diagnosis and treatment of back and neck pain, one of the most common chronic conditions in Canada.

13 Dec 2010

Ascension Orthopedics reports first implantation of PyroTITAN Humeral Resurfacing Implant in France

Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Implant in France. The PyroTITAN was implanted in a 68-year-old patient suffering from painful primary arthritis with synovial osteochondromotosis at Imperial Park Clinic in Nice – making it a surgical first in continental Europe. The patient was discharged from the hospital the next day and reported good pain relief 10 days after surgery.

13 Dec 2010

New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism

Generex Biotechnology Corporation announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

13 Dec 2010

Fracture risk assessment tool for Singaporeans released

Today, the International Osteoporosis Foundation (IOF) and the World Health Organization Collaborating Centre for Metabolic Bone Diseases at the University of Sheffield, UK announced the launch of a FRAX- calculator for Singapore.

13 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

Medical Condition News

Osteoporosis drug reduces bone loss in oral cancer

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

Drug to reverse immunological decline in aging

Novel labeling technique helps researchers to explore DNA chemical modification

Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring

BUSM professor wins 2010 Van Slyke Award for seminal contributions to laboratory medicine

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Majority of brain tumor patients use alternative therapies

Research: Kidney disease caused by autoimmune disease lupus may be twice as lethal in children

Alzheimer’s research update

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Enrollment commences in multi-center clinical trial of CorMatrix ECM for Pericardial Closure

Indian study confirms vitamin D deficiency as risk factor for hip fracture

Elsevier announces special Issue on Fetal Alcohol Spectrum Disorders

iTech Medical receives Health Canada approval for Muscle Pattern Recognition System

Ascension Orthopedics reports first implantation of PyroTITAN Humeral Resurfacing Implant in France

New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism

Fracture risk assessment tool for Singaporeans released

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News